Last edition
News about "neurodevelopmental disorders"
Marvel Biosciences Reports Positive Preclinical Results for MB-204 in Fragile X Syndrome Study
Marvel Biosciences has reported positive preclinical results for its lead drug candidate, MB-204, in a Fragile X syndrome study conducted with the FRAXA Research Foundation. The findings further support the therapy's potential to treat autism spectrum disorder and related neurodevelopmental conditions.
Neurodevelopmental Disorders | 06/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members